nach oben

Cardiovascular Intervention and Therapeutics

Erschienen in:

11.12.2015 | Case Report

Subclinical very late thrombus formation inside and outside the everolimus-eluting stent implanted 3 years prior in a patient with provoked coronary spasms

verfasst von: Shigenori Ito, Hiroyuki Ohmori

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

A 63-year-old man with non-ST-elevation acute myocardial infarction had undergone PROMUS Element stent implantation for stenosis with thrombus in the left main trunk and the proximal left anterior descending artery. A 6-month follow-up angiography revealed no restenosis or stent thrombosis, but severe provoked spasms in three vessels, for which medications were administered. Three years later, the patient experienced new-onset rest angina one morning. Optical coherence tomography revealed subclinical very late stent thromboses inside and outside the stent. The patients experienced a severe spasm. Platelet function was adequately reduced, and the cytochrome P450 2C19 genotype indicated an extensive metabolizer phenotype. The spasm may have caused the thromboses.

Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56:1357–65.CrossRefPubMed

Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv. 2012;5:357–64.CrossRefPubMed

Ito S, Nakasuka K, Morimoto K, Inomata M, Yoshida T, Tamai N, et al. Angiographic and clinical characteristics of patients with acetylcholine-induced coronary vasospasm on follow-up coronary angiography following drug-eluting stent implantation. J Invasive Cardiol. 2011;23:57–64.PubMed

Hung MJ, Hsu KH, Chang NC, Tsimikas S, Hung MY. Prevalence of coronary artery spasm after stent placement and its association with inflammation. Int J Cardiol. 2015;179:252–5.CrossRefPubMed

JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013). Circ J. 2014;78:2779–801.CrossRef

Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138–45.CrossRefPubMed

Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv. 2012;5:12–20.CrossRefPubMed

Miyazaki S, Hiasa Y, Takahashi T, Yano Y, Minami T, Murakami N, et al. In vivo optical coherence tomography of very late drug-eluting stent thrombosis compared with late in-stent restenosis. Circ J. 2012;76:390–8.CrossRefPubMed

Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–34.CrossRefPubMed

10.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. 2011;97:983–90.CrossRefPubMed

11.

Golukhova EZ, Ryabinina MN, Bulaeva NI, Grigorian MV, Kubova M, Serebruany VL. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther. 2015;22:222–30.CrossRefPubMed

12.

Oikonomou E, Papageorgiou N, Papaioannou S, Toutouzas K, Latsios G, Siasos G, et al. Genetic testing and antiplatelet treatment: still way to go? Int J Cardiol. 2015;187:63–5.CrossRefPubMed

13.

Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–22.CrossRefPubMedPubMedCentral

14.

Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cadrdiol. 2008;51:2123–9.CrossRef

15.

Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46:231–6.CrossRefPubMed

16.

Hofma SH, Brouwer J, Velders MA, Van’t Hof AW, Smits PC, Quere M, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: 1-year results of the randomized XAMI (XienceV stent vs. cypher stent in primary PCI for acute myocardial infarction) trial. J Am Coll Cardiol. 2012;60:381–7.CrossRefPubMed

17.

Minami Y, Kaneda H, Inoue M, Ikutomi M, Morita T, Nakajima T. Endothelial dysfunction following drug-eluting stent implantation: a systematic review of the literature. Int J Cardiol. 2013;165:222–8.CrossRefPubMed

18.

Ito S, Nakasuka K, Sekimoto S, Miyata K, Inomata M, Yoshida T, et al. Clinical significance of provoked coronary spasm at chronic stage In patients who underwent successful complete coronary revascularization with first-generation drug-eluting stents. World J Cardiovasc Dis. 2013;3:25–32.CrossRef

19.

Armstrong EJ, Sab S, Singh GD, Lim W, Yeo KK, Waldo SW, et al. Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. JACC Cardiovasc Interv. 2014;7:1105–13.CrossRefPubMed

20.

Hamasaki S, Tei C. Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. J Cardiol. 2011;57:231–8.CrossRefPubMed

21.

Oshima S, Yasue H, Ogawa H, Okumura K, Matsuyama K. Fibrinopeptide A is released into the coronary circulation after coronary spasm. Circulation. 1990;82:2222–5.CrossRefPubMed

22.

Masuda T, Ogawa H, Miyao Y, Yu Q, Misumi I, Sakamoto T, et al. Circadian variation in fibrinolytic activity in patients with variant angina. Br Heart J. 1994;71:156–61.CrossRefPubMedPubMedCentral

23.

Miyamoto S, Ogawa H, Soejima H, Takazoe K, Kajiwara I, Shimomura H, et al. Enhanced platelet aggregation in the coronary circulation after coronary spasm. Thromb Res. 2001;103:377–86.CrossRefPubMed

Titel: Subclinical very late thrombus formation inside and outside the everolimus-eluting stent implanted 3 years prior in a patient with provoked coronary spasms
verfasst von: Shigenori Ito
Hiroyuki Ohmori
Publikationsdatum: 11.12.2015
Verlag: Springer Japan
Erschienen in: Cardiovascular Intervention and Therapeutics / Ausgabe 1/2017
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI: https://doi.org/10.1007/s12928-015-0372-y

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Resolution of severe hemolysis and paravalvular aortic regurgitation employing an Amplatzer Vascular Plug 4: the importance of detailed pre-procedural planning using CT angiography

Potential advantages of the GuideLiner® catheter: insights from optical coherence tomography

Transcatheter valve-in-valve implantation for failed mitral prosthesis: the first experience in Japan

Intravascular ultrasound-guided drug-eluting stent implantation